The effect of radiotherapy dose on survival in stage iii non-small-cell lung cancer patients undergoing definitive chemoradiotherapy

Matthew Koshy, Renu Malik, David J. Sher, Michael Spiotto, Usama Mahmood, Bulent Aydogan, Ralph R. Weichselbaum

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background In this study, we examined trends in the radiotherapy dose prescribed and the effect of dose escalation on survival in patients with stage III lung cancer.

Materials and Methods Radiation dose prescription patterns were analyzed for 38,848 patients in the National Cancer Database with clinical stage III disease who underwent concurrent chemoradiation between 2004 and 2011 to a dose between 57 and 80 Gy. Survival information was available for patients diagnosed from 2004 to 2006 (n = 12,024). Overall survival (OS) was estimated using Kaplan-Meier methods. Cox proportional hazard regression was used to estimate hazard ratios (HRs).

Results The percentage of patients treated to ≥64 Gy increased from 50% in 2004 to 62% in 2011 (P <.001). The 5-year OS was 12% for patients treated between 57 and 59.3 Gy, 14% for patients treated at 59.4 to 62.9 Gy, 16% for patients treated at 63 to 66 Gy and 66.1 to 73.9 Gy, and 13% for patients treated at 74 to 80 Gy (P <.0001). In multivariate analysis, the estimated HR (95% confidence interval) was 1.3 (1.1-1.6) for 57 to 59.3 Gy, 1.0 (0.9-1.2) for 59.4 to 62.9 Gy, 0.9 (0.9-1.2) for 63 to 66 Gy, 0.9 (0.8-1.1) for 66.1 to 73.9 Gy, and 1.0 (referent) for the 74 to 80 Gy cohort. There was no significant difference in the HR for the dose groups > 59.4 Gy compared with the 74 to 80 Gy cohort.

Conclusion There was no improvement in OS with radiotherapy dose escalation beyond 59.4 Gy for patients with unresectable clinical stage III lung cancer treated with chemoradiation.

Original languageEnglish (US)
Pages (from-to)365-371
Number of pages7
JournalClinical Lung Cancer
Volume15
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Survival
Lung Neoplasms
Prescriptions
Databases
Radiation
Neoplasms

Keywords

  • Advanced
  • Cancer
  • Chemoradiation
  • Dose
  • Escalation
  • Locally
  • Lung
  • Radiation
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The effect of radiotherapy dose on survival in stage iii non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. / Koshy, Matthew; Malik, Renu; Sher, David J.; Spiotto, Michael; Mahmood, Usama; Aydogan, Bulent; Weichselbaum, Ralph R.

In: Clinical Lung Cancer, Vol. 15, No. 5, 01.01.2014, p. 365-371.

Research output: Contribution to journalArticle

Koshy, Matthew ; Malik, Renu ; Sher, David J. ; Spiotto, Michael ; Mahmood, Usama ; Aydogan, Bulent ; Weichselbaum, Ralph R. / The effect of radiotherapy dose on survival in stage iii non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. In: Clinical Lung Cancer. 2014 ; Vol. 15, No. 5. pp. 365-371.
@article{e191c40edcd14752a3dd4b3f329c0be1,
title = "The effect of radiotherapy dose on survival in stage iii non-small-cell lung cancer patients undergoing definitive chemoradiotherapy",
abstract = "Background In this study, we examined trends in the radiotherapy dose prescribed and the effect of dose escalation on survival in patients with stage III lung cancer.Materials and Methods Radiation dose prescription patterns were analyzed for 38,848 patients in the National Cancer Database with clinical stage III disease who underwent concurrent chemoradiation between 2004 and 2011 to a dose between 57 and 80 Gy. Survival information was available for patients diagnosed from 2004 to 2006 (n = 12,024). Overall survival (OS) was estimated using Kaplan-Meier methods. Cox proportional hazard regression was used to estimate hazard ratios (HRs).Results The percentage of patients treated to ≥64 Gy increased from 50{\%} in 2004 to 62{\%} in 2011 (P <.001). The 5-year OS was 12{\%} for patients treated between 57 and 59.3 Gy, 14{\%} for patients treated at 59.4 to 62.9 Gy, 16{\%} for patients treated at 63 to 66 Gy and 66.1 to 73.9 Gy, and 13{\%} for patients treated at 74 to 80 Gy (P <.0001). In multivariate analysis, the estimated HR (95{\%} confidence interval) was 1.3 (1.1-1.6) for 57 to 59.3 Gy, 1.0 (0.9-1.2) for 59.4 to 62.9 Gy, 0.9 (0.9-1.2) for 63 to 66 Gy, 0.9 (0.8-1.1) for 66.1 to 73.9 Gy, and 1.0 (referent) for the 74 to 80 Gy cohort. There was no significant difference in the HR for the dose groups > 59.4 Gy compared with the 74 to 80 Gy cohort.Conclusion There was no improvement in OS with radiotherapy dose escalation beyond 59.4 Gy for patients with unresectable clinical stage III lung cancer treated with chemoradiation.",
keywords = "Advanced, Cancer, Chemoradiation, Dose, Escalation, Locally, Lung, Radiation, Therapy",
author = "Matthew Koshy and Renu Malik and Sher, {David J.} and Michael Spiotto and Usama Mahmood and Bulent Aydogan and Weichselbaum, {Ralph R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2014.05.004",
language = "English (US)",
volume = "15",
pages = "365--371",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The effect of radiotherapy dose on survival in stage iii non-small-cell lung cancer patients undergoing definitive chemoradiotherapy

AU - Koshy, Matthew

AU - Malik, Renu

AU - Sher, David J.

AU - Spiotto, Michael

AU - Mahmood, Usama

AU - Aydogan, Bulent

AU - Weichselbaum, Ralph R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background In this study, we examined trends in the radiotherapy dose prescribed and the effect of dose escalation on survival in patients with stage III lung cancer.Materials and Methods Radiation dose prescription patterns were analyzed for 38,848 patients in the National Cancer Database with clinical stage III disease who underwent concurrent chemoradiation between 2004 and 2011 to a dose between 57 and 80 Gy. Survival information was available for patients diagnosed from 2004 to 2006 (n = 12,024). Overall survival (OS) was estimated using Kaplan-Meier methods. Cox proportional hazard regression was used to estimate hazard ratios (HRs).Results The percentage of patients treated to ≥64 Gy increased from 50% in 2004 to 62% in 2011 (P <.001). The 5-year OS was 12% for patients treated between 57 and 59.3 Gy, 14% for patients treated at 59.4 to 62.9 Gy, 16% for patients treated at 63 to 66 Gy and 66.1 to 73.9 Gy, and 13% for patients treated at 74 to 80 Gy (P <.0001). In multivariate analysis, the estimated HR (95% confidence interval) was 1.3 (1.1-1.6) for 57 to 59.3 Gy, 1.0 (0.9-1.2) for 59.4 to 62.9 Gy, 0.9 (0.9-1.2) for 63 to 66 Gy, 0.9 (0.8-1.1) for 66.1 to 73.9 Gy, and 1.0 (referent) for the 74 to 80 Gy cohort. There was no significant difference in the HR for the dose groups > 59.4 Gy compared with the 74 to 80 Gy cohort.Conclusion There was no improvement in OS with radiotherapy dose escalation beyond 59.4 Gy for patients with unresectable clinical stage III lung cancer treated with chemoradiation.

AB - Background In this study, we examined trends in the radiotherapy dose prescribed and the effect of dose escalation on survival in patients with stage III lung cancer.Materials and Methods Radiation dose prescription patterns were analyzed for 38,848 patients in the National Cancer Database with clinical stage III disease who underwent concurrent chemoradiation between 2004 and 2011 to a dose between 57 and 80 Gy. Survival information was available for patients diagnosed from 2004 to 2006 (n = 12,024). Overall survival (OS) was estimated using Kaplan-Meier methods. Cox proportional hazard regression was used to estimate hazard ratios (HRs).Results The percentage of patients treated to ≥64 Gy increased from 50% in 2004 to 62% in 2011 (P <.001). The 5-year OS was 12% for patients treated between 57 and 59.3 Gy, 14% for patients treated at 59.4 to 62.9 Gy, 16% for patients treated at 63 to 66 Gy and 66.1 to 73.9 Gy, and 13% for patients treated at 74 to 80 Gy (P <.0001). In multivariate analysis, the estimated HR (95% confidence interval) was 1.3 (1.1-1.6) for 57 to 59.3 Gy, 1.0 (0.9-1.2) for 59.4 to 62.9 Gy, 0.9 (0.9-1.2) for 63 to 66 Gy, 0.9 (0.8-1.1) for 66.1 to 73.9 Gy, and 1.0 (referent) for the 74 to 80 Gy cohort. There was no significant difference in the HR for the dose groups > 59.4 Gy compared with the 74 to 80 Gy cohort.Conclusion There was no improvement in OS with radiotherapy dose escalation beyond 59.4 Gy for patients with unresectable clinical stage III lung cancer treated with chemoradiation.

KW - Advanced

KW - Cancer

KW - Chemoradiation

KW - Dose

KW - Escalation

KW - Locally

KW - Lung

KW - Radiation

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84908252310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908252310&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2014.05.004

DO - 10.1016/j.cllc.2014.05.004

M3 - Article

C2 - 24984565

AN - SCOPUS:84908252310

VL - 15

SP - 365

EP - 371

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 5

ER -